PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of$ 1. This compares to loss of $2.66 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -16%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 1.21 per share when it actually produced a loss of $1.20, delivering a surprise of 0.83%. Over the last four quarters, the compan ...